Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.59 |
| ▸ | HCK | P08631 | 6/20 | 0.59 |
| ▸ | TNF | P01375 | 5/20 | 0.59 |
| ▸ | SRC | P12931 | 4/20 | 0.59 |
| ▸ | BRAF | P15056 | 3/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.59 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.59 |
| ▸ | CIT | O14578 | 1/20 | 0.59 |
| ▸ | MUSK | O15146 | 1/20 | 0.59 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.59 |
| ▸ | STK10 | O94804 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619959 | 0.84 | MAPK14 (0.69) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL295153 | 0.79 | MAPK14 (0.77) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL29593331 | 0.79 | MAPK14 (0.77) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL6680086 | 0.79 | MAPK14 (0.72) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL295776 | 0.78 | MAPK14 (0.70) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL29593878 | 0.78 | MAPK14 (0.70) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL2533272 | 0.77 | MAPK14 (0.68) | MAPK14MAPK12HCKSRCBRAF | |
| SCHEMBL4601507 | 0.77 | MAPK14 (0.55) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL6298579 | 0.77 | MAPK14 (0.79) | MAPK14MAPK12HCKTNFSRC | |
| SCHEMBL4603200 | 0.76 | MAPK14 (0.55) | MAPK14MAPK12HCKTNFSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599466-B1 | 2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATRORY DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-11-24 | — | — | EP | claimed |
| EP-1599466-A2 | 2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATRORY DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | claimed |
| US-20050032798-A1 | 2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders | BAYER HEALTHCARE LLC | 2005-02-10 | — | — | US | claimed |
| WO-2004078746-A2 | 2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATRORY DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| US-7928227-B2 | Diaryl ureas, which release urea compound when administered to patient, for example, 1-(4-chloro-3(trifluoromethyl)phenyl)-3-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)-2-oxo-(1,3,5-perhydrotriazapine); treatment of cancer, inflammation | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1599466-B1 | 2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATRORY DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1599466-A2 | 2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATRORY DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050032798-A1 | 2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders | BAYER HEALTHCARE LLC | 2005-02-10 | — | — | US | disclosed |
| WO-2004078746-A2 | 2-OXO-1,3,5-PERHYDROTRIAZAPINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE, ANGIOGENESIS, AND INFLAMMATRORY DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032798-A1 | 2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders | HYOU1, HIF1A, HCAR2 | MAPK14 2817/4885MAPK12 3514/4885HCK 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.